TerminatedNot Applicable

Feasibility of Adherence to Light Therapy

Stopped: We received a grant for an expanded feasibility trial that superseded this one.

Canada1 participantsStarted 2022-04-21

Plain-language summary

In this feasibility study, we propose an important question: What factors will affect participant adherence to the daily use of light therapy for maintenance treatment of depression? To answer this question, we will conduct a pilot study of open-label treatment with light therapy in a small sample (n=10) of participants meeting eligibility criteria to determine what factors will challenge or enhance adherence to a standard light therapy protocol.

Who can participate

Age range

19 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \[1\] Outpatients 19 to 65 years of age; * \[2\] Diagnostic and Statistical Manual (DSM)-5 criteria for major depressive disorder (MDD) past or recurrent episode as determined by the Mini International Neuropsychiatric Interview; * \[3\] taking an antidepressant for no more than six months; * \[4\] participant desire to discontinue antidepressant treatment because of adverse effects or other reasons; * \[5\] total score ≤10 on the clinician-rated Montgomery-Asberg Depression Rating Scale \[MADRS\]; * \[6\] Willing and able to complete self-report and online assessments including sufficient fluency in English. Exclusion Criteria: * \[1\] Any psychiatric diagnosis other than MDD that is considered the primary diagnosis, including Bipolar I or Bipolar-II (lifetime); * \[2\] MDD with psychotic features (lifetime); * \[3\] significant personality disorder diagnosis \[e.g., borderline, antisocial\]; * \[4\] High suicidal risk, defined by clinician judgment; * \[5\] History of drug or alcohol abuse, with a severity of at least moderate or severe within 6 months before screening; * \[6\] Significant neurological disorders, head trauma, or other unstable medical conditions; * \[7\] regular use of psychotropic medication other than an antidepressant or benzodiazepines (e.g., antipsychotics, mood stabilizers); * \[8\] history of severe withdrawal effects with antidepressant discontinuation; * \[9\] retinal disease or other eye condition preventing use of bright …

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Adherence Rate

Timeframe: 6 weeks

Trial details

NCT IDNCT04944758

SponsorUniversity of British Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-06-21

Results submitted2022-08-23

View on ClinicalTrials.gov More Major Depression in Remission trials